NASDAQ: AGRX
Agile Therapeutics Inc Stock

$0.32+0.02 (+6.67%)
Updated Jan 24, 2022
AGRX Price
$0.32
Fair Value Price
N/A
Market Cap
$38.97M
52 Week Low
$0.28
52 Week High
$3.77
P/E
-0.41x
P/B
3.65x
P/S
27x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.34M
Earnings
-$69.16M
Gross Margin
-58.8%
Operating Margin
-1,958.02%
Profit Margin
-2,072.4%
Debt to Equity
2.44
Operating Cash Flow
-$66M
Beta
1.09
Next Earnings
Feb 28, 2022
Ex-Dividend
N/A
Next Dividend
N/A

AGRX Overview

Zen Score

High
Medium
Low
Industry Average (21)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AGRX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AGRX is poor value based on its book value relative to its share price (3.65x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.15x)
Valuation
AGRX's cash and short-term investments ($14.74M) cannot cover AGRX's cash burn for the next year ($66.20M), once increasing cash burn (130.85%) is accounted for
Financials
AGRX's profit margin has decreased... subscribe to Premium to read more.
Financials
There are 14 more AGRX due diligence checks available for Premium users.

AGRX News

Valuation

AGRX fair value

Fair Value of AGRX stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
$0.46
Undervalued by
30.00%

AGRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.41x
Industry
131.02x
Market
34.17x

AGRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.65x
Industry
2.15x
AGRX is poor value based... subscribe to Premium to read more.
Valuation

AGRX's financial health

Profit margin

Revenue
$1.3M
Net Income
-$16.8M
Profit Margin
-1,303.2%
AGRX's cash and short-term investments... subscribe to Premium to read more.
Financials
AGRX's profit margin has decreased... subscribe to Premium to read more.
Financials

Assets to liabilities

Assets
$36.7M
Liabilities
$26.0M
Debt to equity
2.44
AGRX's short-term assets ($21.76M) exceed... subscribe to Premium to read more.
Financials
AGRX's short-term assets ($21.76M) exceed... subscribe to Premium to read more.
Financials
AGRX's debt has increased relative... subscribe to Premium to read more.
Financials
AGRX's debt to equity ratio... subscribe to Premium to read more.
Financials

Cash flow

Operating
-$18.6M
Investing
$4.9M
Financing
$2.3M
AGRX's cash and short-term investments... subscribe to Premium to read more.
Financials

Agile Therapeutics Stock FAQ

What is Agile Therapeutics's quote symbol?

(NASDAQ: AGRX) Agile Therapeutics trades on the NASDAQ under the ticker symbol AGRX. Agile Therapeutics stock quotes can also be displayed as NASDAQ: AGRX.

What is the 52 week high and low for Agile Therapeutics (NASDAQ: AGRX)?

(NASDAQ: AGRX) Agile Therapeutics's 52-week high was $3.77, and its 52-week low was $0.28. It is currently -91.49% from its 52-week high and 14.64% from its 52-week low.

How much is Agile Therapeutics stock worth today?

(NASDAQ: AGRX) Agile Therapeutics currently has 121,396,033 outstanding shares. With Agile Therapeutics stock trading at $0.32 per share, the total value of Agile Therapeutics stock (market capitalization) is $38.97M.

Agile Therapeutics stock was originally listed at a price of $5.54 in May 23, 2014. If you had invested in Agile Therapeutics stock at $5.54, your return over the last 7 years would have been -94.21%, for an annualized return of -33.43% (not including any dividends or dividend reinvestments).

How much is Agile Therapeutics's stock price per share?

(NASDAQ: AGRX) Agile Therapeutics stock price per share is $0.32 today (as of Jan 24, 2022).

What is Agile Therapeutics's Market Cap?

(NASDAQ: AGRX) Agile Therapeutics's market cap is $38.97M, as of Jan 25, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Agile Therapeutics's market cap is calculated by multiplying AGRX's current stock price of $0.32 by AGRX's total outstanding shares of 121,396,033.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.